多价值SARS-CoV-2蛋白质疫苗的安全性和免疫性:一个随机的第三阶段试验
Suad Hannawi1, Lixin Yan2, Linda Saifeldin3
1Internal Medicine Department, Al Kuwait-Dubai (ALBaraha) Hospital, Dubai, United Arab Emirates.
EClinicalMedicine
|September 21, 2023
概括
新的多价值COVID-19疫苗SCTV01C和SCTV01E显示出优越的免疫性,与非活化疫苗增剂相比. 在SCTV01E中,针对Delta,Omicron BA.1和BA.5变种的中和抗体反应更高.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- 需要广泛的COVID-19疫苗.
- 对新型多价值疫苗SCTV01E和SCTV01C的评估.
- 与现有的无活化疫苗进行比较.
研究的目的:
- 评估SCTV01E和SCTV01C作为COVID-19疫苗增强剂的安全性和免疫性.
- 通过多价值疫苗诱导的免疫反应与无活化疫苗进行比较.
- 评估针对SARS-CoV-2变种的抗体标位.
主要方法:
- 第三阶段临床试验 (NCT05323461) 涉及参与者用非活化疫苗,SCTV01C或SCTV01E进行增强.
- 测量中和抗体几何平均标位 (GMT) 与德尔塔,欧米克朗BA.1和BA.5变种的测量.
- 对不良事件 (AE) 和严重不良事件 (SAE) 的监测.
主要成果:
- 与非活化疫苗相比,SCTV01C和SCTV01E诱导的GMT对Delta,BA.1和BA.5变种的GMT显著更高.
- 在SCTV01E的测试中,SCTV01E对SCTV01C的测试变种显示出潜在的GMT优势.
- 疫苗表现出类似的安全性概况,大多数是1级或2级的副作用,没有报告的SAE.
结论:
- 多价值疫苗SCTV01C和SCTV01E是安全的,免疫性增强剂的选择.
- SCTV01E对关键的SARS-CoV-2变种表现出优异的中和抗体反应.
- 这些发现支持开发广泛的COVID-19疫苗.
更多相关视频
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
1.9K
00:10Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
7.6K
相关概念视频
Cancer Vaccines
396
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
396
Vaccinations
44.6K
Overview
44.6K
